Claim Missing Document
Check
Articles

Found 2 Documents
Search

Needle Aspiration in Tuberculosis-Associated Secondary Spontaneous Pneumothorax Candrawati, Ni Wayan; Indraswari, Putu Gita; Komalasari, Ni Luh Gede Yoni
Jurnal Respirasi Vol. 10 No. 1 (2024): January 2024
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v10-I.1.2024.50-54

Abstract

Introduction: The management of tuberculosis-associated secondary spontaneous pneumothorax mostly requires chest tube insertion for complete drainage and resolution. We reported a case of tuberculosis-associated secondary spontaneous pneumothorax that improved with needle aspiration. Case: A 29-year-old female with pulmonary tuberculosis presented with sudden onset shortness of breath. Chest examination revealed asymmetry, decreased vocal fremitus, hypersonor, and decreased vesicular sound in the right lung field. Chest radiograph showed right pneumothorax with a 2 cm intrapleural distance. Needle aspiration was performed because the patient refused chest tube insertion. The first needle aspiration evacuated approximately 615 cc of air. The second needle aspiration was repeated 24 hours later due to clinical deterioration, and 610 cc of air was evacuated. Chest radiograph evaluation on the 6th day of treatment showed no pneumothorax. During hospitalization, the patient received oxygen therapy, anti-tuberculosis drugs, chest physiotherapy, and other symptomatic therapies such as mucolytics. The patient's condition improved, and she was discharged on the 9th day of hospitalization. Tuberculosis-associated secondary pneumothorax occurs in 1-3% of cases. Conclusion: Needle aspiration is a therapeutic modality for tuberculosis-associated secondary spontaneous pneumothorax. This modality has several advantages, including shorter length of stay, less cost and pain, and fewer complications. Needle aspiration combined with oxygen therapy, anti-tuberculosis drugs, and chest physiotherapy should be the modality of treatment for tuberculosis-associated secondary pneumothorax.
Periorbital Necrotizing Fasciitis in Lung Adenocarcinoma Patient Receiving Afatinib: A Case Report Kusumawardani, Ida Ayu Jasminarti Dwi; Tan, Leviani; Indraswari, Putu Gita; Yuliawati, Putu; Wiradana, A.A. Gde Agung Anom Arie
Indonesian Journal of Cancer Vol 20, No 1 (2026): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i1.1417

Abstract

Background: Afatinib is a second-generation Tyrosine Kinase Inhibitor (TKI) approved by the Food and Drug Administration (FDA) as first-line therapy for advanced Non-small cell lung cancer (NSCLC) with distant organ metastasis. However, afatinib has been reported to cause several side effects. Here, we report a case of periorbital necrotizing fasciitis, potentially associated with afatinib use, presenting as a grade 3 side effect in a 59-year-old woman with stage IVB lung adenocarcinoma. This is the first literature reporting afatinib-related periorbital necrotizing fasciitis, a rare sight-threatening infection.Case Presentation: A 59-year-old female patient came to the Emergency Room with a protruding left eye, which is accompanied by redness, purulent discharge, and a blackish wound around the left eye area for the last 5 days. The patient had been diagnosed with stage IVB lung adenocarcinoma (T4N3M1c) six months ago. Previously, she underwent chemotherapy with a combination of Gemcitabine and Carboplatin. The patient then underwent 20 cycles of radiotherapy followed by immunotherapy using afatinib. The patient was then admitted with suspected necrotizing fasciitis of the left periorbital area due to side effects of afatinib. She was given ceftriaxone 2 grams every 24 hours intravenously (IV), analgesics IV, methylprednisolone IV, gentamicin eye drops, and regular wound care. After several days of treatment, the patient had significant improvement. Afatinib therapy was temporarily stopped. Re-evaluation at one month showed significant improvement in the patient's left periorbital area. Afatinib therapy was then continued at a lower dose of 30 mg every 24 hours.Conclusions: Good education and caution are still needed for patients who were given afatinib. More studies on the side effects of afatinib are needed to identify predisposing factors and establish a consensus on the management of afatinib-induced periorbital necrotizing fasciitis in NSCLC patients.